VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that VistaGen Vice President, Translational Medicine Dr. Louis Monti and VistaGen CNS Clinical and Regulatory Advisory Board Member Dr. Michael Liebowitz authored an article published in CNS Spectrums, a Cambridge University Press journal. The article covers the proposed mechanism of action of VistaGen’s investigational neuroactive nasal sprays, PH94B and PH10, currently in development as potential rapid-onset treatments for anxiety and depression disorders.* The publication details the proposed neural circuits mediating the mechanism of action of pherines, including PH94B and PH10, which are synthetic neuroactive steroids designed to engage nasal chemosensory receptors and produce rapid-onset anxiolytic and antidepressant effects. “PH94B and PH10 were discovered and developed for their specific therapeutic potential to treat anxiety and depression disorders, representing a new class of neuropharmaceuticals,” said Dr. Monti. “When current anxiolytics and antidepressants drugs are administered systemically, milligram-level doses of the drugs are often needed to achieve the desired therapeutic effects. In contrast, with the innovative pharmacology of PH94B and PH10, we believe only microgram-level doses administered intranasally onto the receptors in the nasal passage are required to achieve the desired neural activity.”
To view the full press release, visit https://ibn.fm/WeiCS
About VistaGen Therapeutics Inc.
VistaGen is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment